论文部分内容阅读
发表于国际杂志the Journal of Cell Biology上的一项研究论文中,来自北海道大学医学院的研究人员通过研究发现,在特定乳腺癌中被上调的一种特殊代谢通路或可通过激活细胞信号蛋白Arf6来促进疾病的恶化,研究者表示,这项题为“P53-and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance”的研究报告表明,他汀样的药物或可有效治疗那些机体中Arf6信号蛋白高表达的乳腺癌患者。甲羟戊酸途径(MVP)是一种特殊的代谢通路,其可以帮助产生组成一系列生物性分子的基本元件,包括从胆固醇到长链脂质分子等;而肿瘤
In a research paper published in the Journal of Cell Biology, researchers from Hokkaido University School of Medicine found that a specific metabolic pathway that is up-regulated in specific breast cancers can be activated by activating the cellular signaling protein Arf6 To promote the worsening of the disease, the investigators said in a research paper entitled “P53-and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance” that statin-like drugs may be effective in treating Arf6 High expression of signaling proteins in breast cancer patients. The mevalonate pathway (MVP) is a special metabolic pathway that helps produce the basic elements that make up a range of biological molecules, from cholesterol to long-chain lipid molecules; and tumors